Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 16 de 16
Filter
1.
Rev. neurol. (Ed. impr.) ; 60(supl.1): s95-s101, mar. 2015. tab
Article in Spanish | IBECS | ID: ibc-134379

ABSTRACT

el presente artículo analiza las críticas generadas a partir de la publicación del Manual diagnóstico y estadístico de los trastornos mentales, quinta edición (DSM-5), ya anunciadas parcialmente durante las últimas fases de su elaboración. Una parte de las críticas se ha centrado en los cambios de los criterios diagnósticos para determinados trastornos y en la incorporación al DSM de nuevas entidades. Sin embargo, otra vertiente crítica va dirigida a la falta de validez de los diagnósticos del DSM, por cuyo motivo se ha cuestionado su eficiencia en el campo de la investigación. El fallo básico del DSM se centra en la incoherencia de un modelo basado en un amplio repertorio de definiciones de entidades categóricas, todas ellas con un alto componente de comorbilidad. Como propuesta para superar el bloqueo generado en la investigación y la parquedad de avances terapéuticos, el Instituto Nacional de Salud Mental de Estados Unidos ha propuesto una estrategia de investigación cuyo punto de partida se sustenta en la identificación y el estudio de las dimensiones básicas de las disfunciones que se presentan de modo transversal en los trastornos mentales (AU)


This paper analyses the criticism prompted by the publication of the Diagnostic and statistical manual of mental disorders, fifth edition (DSM-5), which was already foreseen to a certain extent during the final stages of its drafting. Part of the criticism has focused on the changes in the diagnostic criteria for certain disorders and the incorporation of new entities into the DSM. Another line of criticism, however, is aimed at the lack of diagnostic validity of the DSM, which has led to its efficiency in the research field being questioned. The basic underlying flaw in the DSM is the incoherence of a model based on a wide range of definitions of categorical entities, all of which have a high element of comorbidity. As a proposal to overcome the blockage generated in research and the scarcity of therapeutic advances, the US National Institute of Mental Health has put forward a research strategy based on identifying and studying the fundamental dimensions of the dysfunctions that present transversally in mental disorders (AU)


Subject(s)
Humans , Male , Female , Manuals as Topic/standards , Review Literature as Topic , Autistic Disorder/diagnosis , Cell Biology/education , Cell Biology/ethics , National Institute of Mental Health (U.S.)/legislation & jurisprudence , Publications for Science Diffusion , Autistic Disorder/psychology , Cell Biology/legislation & jurisprudence , Cell Biology/standards , Matched-Pair Analysis , National Institute of Mental Health (U.S.)/statistics & numerical data
2.
Mol Biol Cell ; 23(21): 4171-4, 2012 Nov.
Article in English | MEDLINE | ID: mdl-23112231

ABSTRACT

I trace how the American Society for Cell Biology became a strong political advocate for the scientific community. I celebrate how good leadership and an effective staff enabled its energetic volunteer organization to have an impact, but I also ask how the effort can be made more successful.


Subject(s)
Cell Biology , Politics , Public Policy , Societies, Scientific , Advisory Committees/legislation & jurisprudence , Biomedical Research/legislation & jurisprudence , Cell Biology/legislation & jurisprudence , Public Policy/legislation & jurisprudence , Societies, Scientific/legislation & jurisprudence
3.
J Telemed Telecare ; 6 Suppl 1: S143-5, 2000.
Article in English | MEDLINE | ID: mdl-10794001

ABSTRACT

The medicolegal issues surrounding telepathology and telecytology in Japan have been partly resolved since the government declared that telediagnosis in these fields using a microscope is essentially a medical practice between doctors. Thus it does not contravene article 20 of the law pertaining to medical practice in Japan, which states that there must be an actual face-to-face encounter between the doctor performing any diagnostic or treatment episode and the patient. It is, however, only beginning to be recognized that the medicolegal issues surrounding telepathology and telecytology depend on factors such as the type of system used (e.g. active versus passive). In an active diagnostic system, the telepathologist or telecytopathologist can control a robotic microscope at the remote site, while in a passive diagnostic system the telepathologist or telecytopathologist makes the diagnosis based on the microscope images that have been selected, and transmitted, by someone in the remote hospital. In the former case the interpreting telepathologist or telecytopathologist must assume most of the responsibility for the diagnostic process, while in the latter more responsibility must be assumed by those at the remote site. The duties and responsibilities of all participants in the telediagnostic process, whatever the system employed, must be determined. We have established working guidelines for telepathological and telecytological diagnoses to help achieve this and hence ensure safe and effective clinical practice.


Subject(s)
Telepathology/legislation & jurisprudence , Cell Biology/legislation & jurisprudence , Humans , Interprofessional Relations , Japan
4.
Diagn Cytopathol ; 22(3): 203-6, 2000 Mar.
Article in English | MEDLINE | ID: mdl-10680006

ABSTRACT

The paper traces the history of cytopathology in the U.K. from the time of the pioneers in the last century to the 1930s and continues with the development of cervical and breast screening, with reference to training and quality control, to the present time. Diagn. Cytopathol. 2000;22:203-206.


Subject(s)
Cell Biology/history , Pathology/history , Cell Biology/education , Cell Biology/legislation & jurisprudence , History, 19th Century , History, 20th Century , Pathology/education , Pathology/legislation & jurisprudence , United Kingdom
5.
Acta Cytol ; 42(1): 76-119; discussion 120-32, 1998.
Article in English | MEDLINE | ID: mdl-9479326

ABSTRACT

ISSUES: Increasing litigation over alleged false negative cervical cytologic (CC) smears threatens the viability of this test for cervical cancer detection. The problem appears to be largely American but is beginning to appear in some other countries. In the vast majority of cases there is either a settlement or jury verdict for the plaintiff based largely on the testimony of expert witnesses. Cases are judged on an individual basis without significant consideration of the general performance of the CC smear in laboratories operating in compliance with a wide array of laboratory regulations and with documented and comprehensive quality control practices in place. It is acknowledged that there are problem laboratories and cytology practitioners. There is an emerging issue of automated preparation and screening devices and issues of informed patient consent. CONSENSUS POSITION: Cytology professionals have done an extraordinary and commendable job of educating the public about the benefits of the CC smear. We have been less successful and conscientious about explaining and defining the limitations of the CC test. There is a need for public and professional education as to the benefits and limitations of the CC smear for cervical cancer detection. The process suggested is to work with women's groups, public health agencies, government agencies, and state and national legislatures and to coordinate professional committees working on liability issues. Contextual information could be included with the CC smear report to indicate that a negative report confers a low probability of developing cervical cancer. It is suggested that appropriate language and a menu of statements be developed. Increased efforts should be directed to physician education with respect to informed consent concerning the benefits and limitations of CC smear testing and the application of new technology to improve smear accuracy. The process should include development of appropriate statements on the use of alternative technology. The profession should develop "process guidelines" for review of CC smears in the context of possible litigation, including standardized methods for blind slide review of smears that reduce or eliminate context and outcome bias. It is suggested that review panels be anonymous, that the process be standardized and that there be limitations on liability for participating organizations. Professional cytopathology and pathology societies should formulate acceptable guidelines for expert witnesses. The standards should be applicable to both defendant and plaintiff experts. All materials to the extent practical, including consultant opinions, should be available for peer review. Professional cytopathology and pathology societies should monitor expert testimony for objectivity and scientific accuracy. ONGOING ISSUES: For the near future, litigation will continue to focus on false negative CC smears on a case-by-case basis. Laboratories and individuals can reduce the risk of malpractice liability by directing their attention to proactive quality control and quality assurance methods. In the final analysis, consumer education about the benefits and limitations of the test is key to limiting malpractice claims. To stem the tide of continued medicolegal challenges to the integrity of cytology practice, the cytology community has now focused its efforts on developing and utilizing standards that convey to patients, attorneys and cytologists the contemporary status of and reasonable expectations for the practice of cytology. Guidelines such as those for uniform reporting terminology and clinical management of cervical abnormalities form the basis of cytology practice standards on which legal standards of practice can be based. Consensus conference reports, clinical management trials and scientifically valid studies of false negative rates that analyze the type, frequency and cause of missed cases represent sounder methods of establishing defensible


Subject(s)
Cell Biology/legislation & jurisprudence , Health Education , Jurisprudence , Malpractice , Uterine Cervical Neoplasms/diagnosis , Vaginal Smears , Confidentiality , Defensive Medicine , Diagnostic Errors , Disease Progression , Expert Testimony , False Negative Reactions , Female , Humans , Insurance, Liability , Mass Screening/legislation & jurisprudence , Medical History Taking , Observer Variation , Patient Advocacy , Predictive Value of Tests , Professional Practice/standards , Retrospective Studies , Single-Blind Method , Truth Disclosure , United States , Uterine Cervical Diseases/classification , Uterine Cervical Diseases/diagnosis , Uterine Cervical Diseases/pathology , Uterine Cervical Neoplasms/prevention & control
6.
MMWR Recomm Rep ; 46(RR-17): 1-19, 1997 Dec 19.
Article in English | MEDLINE | ID: mdl-9409538

ABSTRACT

The Papanicolaou test--or Pap smear test--is one of the most effective cancer screening tests available, and its ability to detect premalignant conditions has contributed to the decline in cervical cancer morbidity and mortality in the United States since its development in 1941. The success of this screening test has created confidence among women, health-care providers, and public health officials. However, this screening tool is not perfect: false-negative findings are a special concern because they can delay necessary follow-up of and treatment for women who have cervical cancer precursor lesions or invasive cervical cancer. Recent media attention has focused on cytology laboratories that have been closed as a result of deficiencies (including a high proportion of false-negative reports), and in some states legal action has been taken against individual laboratories. With the advent of revised federal regulations implementing the Clinical Laboratory Improvement Amendments (CLIA) of 1988, scrutiny of the quality of cytology laboratory practice has increased. Between 1992 and 1994, a total of 10 cytology laboratories were closed by regulatory action of the Health Care Financing Administration because they were considered a threat to the public's health. Although such closures represent <1% of CLIA-certified cytology laboratories, the attendant publicity may trigger anxiety among women. Public health officials must respond to those concerns with appropriate clinical and community actions to ensure the health and safety of women whose Pap smears were evaluated by the closed laboratories. There are no published recommendations to help develop a public health response to the regulatory closure of a cervical cytology laboratory. In April 1994, the Association of State and Territorial Public Health Laboratory Directors, through a cooperative agreement with CDC, convened a working group to provide background on the current practice of clinical cervical cytology in the United States, summarize the CLIA regulations that established specific quality assurance standards for this specialty, and recommend actions that a public health agency may initiate to deliver a measured response to laboratory closings and other regulatory sanctions. This report includes this background and summary of the workshop. The working group made three recommendations: (a) public health officials should plan for a cervical cytology laboratory closure, then, when a laboratory is closed by regulatory action, they should (b) assess the severity of the situation and determine an appropriate response and (c) provide accurate, timely information to the public.


Subject(s)
Cell Biology/standards , Laboratories/standards , Papanicolaou Test , Vaginal Smears/standards , Cell Biology/legislation & jurisprudence , False Negative Reactions , Female , Guidelines as Topic , Health Facility Closure , Humans , Laboratories/legislation & jurisprudence , Mass Screening , Public Health , Quality Control , United States , Uterine Cervical Neoplasms/prevention & control
10.
Diagn Cytopathol ; 15(2): 91-2, 1996 Aug.
Article in English | MEDLINE | ID: mdl-8872427
15.
Md Med J ; 40(2): 107-11, 1991 Feb.
Article in English | MEDLINE | ID: mdl-1847738

ABSTRACT

In 1990, the Department of Health and Mental Hygiene provided proficiency-testing to seventy-three cytology laboratories, and 293 technical employees. Sixty-three of these labs, 132 of 154 pathologists, and 130 of 139 cytotechnologists passed without having to undergo retesting or retraining. Failing laboratories accounted for approximately 2 percent of the cervicovaginal slides diagnosed in 1989. Labs with the lowest passing rates were small ones operated by single pathologists not employing cytotechnologists. Eight pathologists either surrendered their state permit or were required to obtain additional training; no cytotechnologist required additional training.


Subject(s)
Cell Biology/standards , Cytological Techniques/standards , Licensure/legislation & jurisprudence , Cell Biology/legislation & jurisprudence , Evaluation Studies as Topic , Female , Humans , Maryland , Pilot Projects , Vaginal Smears/standards
SELECTION OF CITATIONS
SEARCH DETAIL
...